Related Experiment Video

Updated: Jul 24, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.8K

Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer

T Olivier1, V Prasad2

  • 1Department of Oncology, Geneva University Hospital, Geneva, Switzerland.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|July 9, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

4.6K

Related Experiment Videos

Last Updated: Jul 24, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.8K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

4.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

Articles linked to this work by shared authors, journal, and citation graph.

Precision Studies and Searches for CP Asymmetries in the Inclusive Decay Λ_{c}^{+}→ΛX.

Physical review letters·2026

First Energy-Scan Measurement of e^{+}e^{-}→K^{+}K^{-} around the ψ(2S) Resonance.

Physical review letters·2026

First Experimental Constraint on the Scalar Current in the D^{0(+)}→K[over ¯]ℓ^{+}ν_{ℓ} Transition.

Physical review letters·2026

Measurements of the Absolute Branching Fraction of the Semileptonic Decay Ξ^{-}→Λe^{-}ν[over ¯]_{e} and the Axial Charge of Ξ^{-}.

Physical review letters·2026

First Observation of D^{0(+)}→K[over ¯]ωe^{+}ν_{e} and Determination of the Branching Fraction of K[over ¯]_{1}(1270)→K[over ¯]ω.

Physical review letters·2026

Measurement of the Λ electric dipole moment with an entangled baryon-antibaryon system.

Science (New York, N.Y.)·2026

Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Efficacy of Cryotherapy in Preventing Taxane-Induced Neuropathy: The CryoPac Randomised Controlled Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us